LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$BCAB
BioAtla, Inc.
UNITED STATESLAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $BCAB
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| RADAR SCANNING: WAITING FOR NEXT CATALYST | ||||||
Exact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
Intelligence Brief
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal… Read full dossier